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creativecommons.org/licenses/by/4.0/).Abnormal uterine bleeding (AUB) is a common and debilitating
condition with high direct and indirect costs. AUB frequently co-
exists with ﬁbroids, but the relationship between the two re-
mains incompletely understood and in many women the identi-
ﬁcation of ﬁbroids may be incidental to a menstrual bleeding
complaint. A structured approach for establishing the cause using
the Federation International de Gynecologie et d'Obstetrique
(FIGO) PALM-COEIN (Polyp, Adenomyosis, Leiomyoma, Malig-
nancy (and hyperplasia), Coagulopathy, Ovulatory disorders,
Endometrial, Iatrogenic and Not otherwise classiﬁed) classiﬁcation
system will facilitate accurate diagnosis and inform treatment
options. Ofﬁce hysteroscopy and increasing sophisticated imaging
will assist provision of robust evidence for the underlying cause.
Increased availability of medical options has expanded the choice
for women and many will no longer need to recourse to potentially
complicated surgery. Treatment must remain individualised and
encompass the impact of pressure symptoms, desire for retention
of fertility and contraceptive needs, as well as address the man-
agement of AUB in order to achieve improved quality of life.
© 2015 The Authors. Published by Elsevier Ltd. This is an open
access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).Background
Abnormal uterine bleeding (AUB) is a signiﬁcant clinical entity. AUB and its sub group, heavy men-
strual bleeding (HMB), are common conditions affecting 14e25% of women of reproductive age [1,2] andductive Health, The Queen's Medical Research Institute, 47 Little France
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UK, over 800,000 women seek help for AUB annually [3]. Along with the direct impact on the woman
and her family, there are signiﬁcant costs to both economy and health service. A US study reported
ﬁnancial losses of >$2000 per patient per annum due to work absence and homemanagement costs [4].
AUB is the fourth most common reason for referral to UK gynaecological services [5]. A recent national
audit in England and Wales (RCOG HMB audit) reported that at 1-year post referral, only a third of
women (including those managed with surgery) were ‘satisﬁed’ (or better) at the prospect of current
menstrual symptoms continuing, as currently experienced, for the next 5 years [6]. While there may be
relief from HMB during pregnancy and lactation, and an end to the problem at menopause, women
affected will tend to suffer the adverse impacts of AUB overwhat should be the prime years of their lives.
Fibroids (leiomyoma) represent the most common tumour of women; by the age of 50, almost 70%
of white women and >80% of black women will have developed at least one ﬁbroid [7]. Fibroids are
associated with subfertility, miscarriage, preterm labour and obstruction of labour. In addition, they
may cause discomfort and pressure symptoms, typically urinary. In rare circumstances, at larger sizes,
they may cause compression of the renal tract and pelvic vasculature leading to impaired renal
function and venous thromboembolism, respectively. Conversely, many women with ﬁbroids will be
entirely asymptomatic [8]. However, many women most commonly present to gynaecological services
with AUB and associated iron-deﬁciency anaemia. For women with uterine ﬁbroids, everyday life is
often disrupted and ﬁbroids remain a leading indication for hysterectomy [9,10]. Conservative esti-
mates of annual direct treatment costs and indirect costs from lost work hours as a result of ﬁbroids are
$4.1e9.4 billion and $1.55e17.2 billion, respectively [11]. The mechanisms, however, linking AUB and
ﬁbroids remain incompletely understood.
As women increasingly defer pregnancy, fertility preservation is critical and newer medical options
offer genuine effective relief for both AUB and other symptoms associated with ﬁbroids. This review
addresses the causes of AUB and approach to assessment and general principles of management of the
pre-menopausal woman with ﬁbroids.
Deﬁnitions
AUB was redeﬁned by Federation International de Gynecologie et d'Obstetrique (FIGO) in 2009 by
the FIGO Menstrual Disorders Group (FMDG) [12,13]. This was in order to standardise deﬁnitions,
nomenclature and the underlying categories of aetiology. It was hoped that this would facilitate ease of
investigation and comparison of similar patient populations and thereby aid research and improve
evidence-based care; this would also be a practical tool for assessing contributing aetiologies.
Chronic AUB was deﬁned as ‘bleeding from the uterine corpus that is abnormal in volume, regu-
larity and/or timing that has been present for themajority of the last 6months’ [13]. Values outwith the
accepted 5e95th percentiles indicated abnormality (Table 1).
With regard to volume, however, both the Royal College of Obstetricians and Gynaecologists (RCOG)
and American College of Obstetricians and Gynecologists (ACOG) prefer the patient-centred deﬁnition
of HMB, ‘excessive menstrual blood loss which interferes with a woman's physical, social, emotional
and/or material quality of life’ [3], as an indication for investigation and treatment options. As such,
objective measurements of volume are usually the preserve of research studies and surrogates such a
pictorial blood-loss assessment chart (PBAC) scores are not recommended in routine clinical practice.
FIGO classiﬁcation of cause: ‘PALM-COEIN’
Once bleeding is deﬁned as being abnormal, the acronym PALM-COEIN is now being increasingly
used for categorising causes: Polyp, Adenomyosis, Leiomyoma, Malignancy (and hyperplasia), Coa-
gulopathy, Ovulatory disorders, Endometrial, Iatrogenic and Not otherwise classiﬁed [13]. The ‘PALM’
are assessed visually (imaging and histopathology) and the ‘COEIN’ are non-structural (Fig. 1).
Depending on the site, leiomyoma (ﬁbroids) are further subdivided into submucosal (SM) and other
(O) and then into nine tertiary categories adapted from theWamsteker classiﬁcation [14] (Fig. 2). These
have been adopted by the European Society for Human Reproduction and Embryology (ESHRE) and
used by the European Society for Gynaecological Endoscopy (ESGE).
Table 1
Suggested Normal limits for menstrual parameters. Adapted from Fraser et al. [12].
Clinical Parameter Descriptive term Normal limits (5e95th percentiles)
Frequency of menses (days) Frequent
Normal
Infrequent
<24
24e38
>38
Regularity of menses, cycle to cycle
(Variation in days over 12 months)
Absent
Regular
Irregular
No bleeding
Variation ± 2e20 days
Variation >20 days
Duration of ﬂow (days) Prolonged
Normal
Shortened
>8.0
4.5e8.0
<4.5
Volume of monthly blood loss (mL) Heavy
Normal
Light
>80
5e80
<5
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The relationship between AUB and ﬁbroids remains incompletely understood. The obvious paradox
is that many women have ﬁbroids but also have entirely normal bleeding patterns. Fibroids are also
highly prevalent in women presenting with AUB.
Previous postulated theories include an increased endometrial surface area and the presence of
fragile and engorged vasculature in the perimyoma environment [15]. The increase in vascular ﬂow
observed along with these enlarged vessels can overcome platelet action [16]. There is increasing
knowledge regarding the complex cellular and molecular changes found in association with ﬁbroids,
with impact on angiogenesis, alteration in vasoactive substrates and growth factors as well as alteration
in coagulation [16]. The effect of ﬁbroids on endometrial function is now thought to represent a ﬁeld
change within the uterine cavity rather than limited to regions overlying the myoma(s). Some of these
changes may have an impact on endometrial receptivity and implantation as well as AUB [17,18].
Matrix metalloproteinase (MMP) 2 and 11 levels are increased in ﬁbroids (with MMP 1 and 3 un-
changed) [19,20], but the impact on endometrial bleeding is unclear. Expression of vascular endothelial
growth factor (VEGF), basic ﬁbroblast growth factor (bFGF), heparin-binding epidermal growth factor,
platelet-derived growth factor (PDGF), parathyroid hormone-related protein (PTHrP) and prolactin is
altered in women with ﬁbroids [16]. VEGF, bFGF, PDGF and PTHrP all have potential angiogenic effects
but their speciﬁc role within the endometrium in women with ﬁbroids has yet to be determined [17].
There is alteration of plasminogen modulators and this may impact on endometrial haemostasis
and repair [16]. Transforming growth factor beta (TGF-b) is produced in excess in the endometrium in
womenwith ﬁbroids and is associatedwith reduced levels of plasminogen activator inhibitor-1 (PAI-1),
thrombomodulin and antithrombin III, both in vivo and in endometrial stromal cells treated in vitro
with TGF-b [18]. This may represent a putative mechanism for some cases of AUB observed in the
context of ﬁbroids and may in the future offer a potential therapeutic target.
In women with ﬁbroids, alterations in the blood plasma levels of circulating interleukin (IL)-13, IL-
17 and IL-10 have been reported [21]. Whether these variations affect immune function and inﬂam-
mation implicated in endometrial breakdown and repair remains unknown.
With regard to the location of ﬁbroids, it was previously thought that those women with SM ﬁ-
broids, particularlywith those distorting the cavity, weremore likely to present with HMB [15]. There is
current debate that women with signiﬁcant cavity distortion represent additional therapeutic
challenges.Other causes of AUB
The PALM-COEIN classiﬁcation system accepts that women may have more than one underlying
aetiology and also that often in the case of structural abnormalities, many women may in fact be
asymptomatic.
Fig. 1. FIGO classiﬁcation of causes of AUB; ‘PALM COEIN’.
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Endometrial polyps are epithelial proliferations arising from the endometrial stroma and glands.
The majority are asymptomatic. The contribution of polyps to AUB varies widely ranging from 3.7% to
65% [22,23], but it is widely accepted [24]. The incidence of polyps as with ﬁbroids increases with age
and both pathologies may frequently co-exist, or suspected polyps visualised on transvaginal ultra-
sound scanning (TV-USS) may be mistaken for SM ﬁbroids and vice-versa [25].
Adenomyosis (AUB-A)
The relationship between adenomyosis and AUB remains unclear [26], particularly with regard to
wide variations in histopathological diagnosis reﬂecting variations in criteria used and also improved
radiological diagnosis. Typically, adenomyosis is associated with increasing age and may co-exist with
ﬁbroids. Furthermore, adenomyosis may be both focal and diffuse and it may be harder to establish
diagnosis if ﬁbroids are also present [27].
Malignancy (AUB-M)
Endometrial cancer is the most common gynaecological malignancy in the western world. His-
torically, endometrial cancer has rarely occurred in premenopausal women; however, with increasing
Fig. 2. Tertiary classiﬁcation of AUB-L (adapted from Munro et al. [13]).
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malignancy has markedly increased in frequency. Between 1992e1994 and 2009e2011, the European
age-standardised rates of uterine cancer in the UK have increased by 48% [28]. With the reclassiﬁcation
by the WHO from hyperplasia to endometrial intraepithelial neoplasia (EIN), the current prevalence of
premalignant disease is unknown. The evaluation of the endometriummay be affected by distortion of
the uterine cavity by ﬁbroids, and as such, the co-existing pathology may delay diagnosis.
The diagnosis of cervical cancer should be considered, particularly with persistent intermenstrual
bleeding, and rarely ovarian cancer may present with AUB.
Uterine sarcoma have been reported as rare (3e7/100,000 in the USA) [29] but maybe a cause of
AUB-M. A recent meta-analysis reported that leiomyosarcoma are unexpectedly diagnosed following
surgery for anticipated ‘benign’ myomas in 2.94 per 1000 women (one in 340 women) [30,31]. Race is
the only commonality between leiomyosarcoma and leiomyoma with black women having an
approximately twofold increased risk [29]. The risk of development of leiomyosarcoma is reported to
increasewith agewith <1 case per 500 amongwomen aged under 30 years to one in 98 amongwomen
in the age range 75e79 years [30,31]. Other risk factors for uterine leiomyosarcoma include the long-
term use of tamoxifen [32], previous pelvic radiation therapy [33] and rare inherited disorders such as
hereditary leiomyomatosis and renal cell carcinoma (HLRCC) [34].
Interestingly, the previously held viewwas that a rapidly enlarging uterus would raise the suspicion
for malignancy. This is now no longer held to be true as benign ﬁbroids can grow rapidly and sarcomas
grow slowly [35,36]. However, more objective investigations are still lacking. Both ultrasound scanning
(USS) and magnetic resonance imaging (MRI) do not as yet have robust criteria to accurately predict
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dictor/biomarker has recently altered surgical practice because morcellation of an unsuspected leio-
myosarcoma increases dissemination [38].
If malignancy or premalignancy is found along with AUB classiﬁcation, the pathology should be
described and staged utilising the appropriate WHO/FIGO systems [39].
Coagulopathy (AUB-C)
Coagulopathies are reported to affect 13% [40] of the women presenting with HMB. The majority of
these women suffer from Von Willebrand disease [40]. Systemic disorders of haemostasis may be
identiﬁed in 90% of women using a structured history [41,42] (Table 2).
If 1, 2 or 3 (see Table 2) is ascertained, it indicates positive screen, and further referral for appro-
priate investigation should be considered.
Anticoagulant and antiplatelet therapy hitherto has been considered as a part of ‘AUB-C’ (rather
than AUB-I). Compression caused by a large ﬁbroid uterusmay lead to venous thromboembolism (VTE).
Bleeding previously deemed as AUB-Lmay be exacerbated by subsequent anticoagulation and presents
additional management challenges.
Ovulatory (AUB-O)
Anovulatory cycles may contribute to AUB by unopposed oestrogen effects on the endometrium
causing marked proliferation and thickening resulting in HMB along with an altered frequency of
menstruation. This is observed at the extremes of reproductive age; however, impact on the HPO axis
along with endocrinopathies is also present. The latter include polycystic ovarian syndrome (PCOS),
hyperprolactinaemia, hypothyroidism as well as factors such as obesity, anorexia, weight loss, mental
stress and extreme exercise. Typically, women in this group have menstrual cycles that fall out with 38
days or have a variation of >21 days. Drugs that affect dopamine levels, with their attendant effects on
the HPO axis, also currently fall under this category rather than AUB-I. In womenwith ﬁbroids, the co-
existing ovulatory dysfunction may exacerbate menstrual loss.
The FIGO AUB classiﬁcation system is a dynamic system with feedback and contemporary debate
informing future revisions [13]. The position of drug therapies affecting AUB is currently under review
with regard to whether anticoagulant/antiplatelet therapies and drugs affecting the HPO axis may be
better placed in ‘AUB-I’.
Endometrial (AUB-E)
AUB that occurs in the context of a structurally normal uteruswith regularmenstrual cycles without
evidence of coagulopathy is likely to have an underlying endometrial cause. Endometrial function in
the context of menstruation and its disorders is still not fully understood and remains an area of active
scientiﬁc enquiry, particularly the complexities of the sequence of events triggered by progesteroneTable 2
Structured history for coagulopathy screen. Adapted from Koudies et al. [42].
Criteria
1. Heavy bleeding since the menarche
2. One of the following:
 Postpartum haemorrhage
 Surgical-related bleeding
 Bleeding associated with dental work
3. Two or more of the following:
 Bruising 1e2 times/month
 Epistaxis 1e2 times per/month
 Frequent gum bleeding
 Family history of bleeding problems
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haemostasis and angiogenesis all play crucial roles in the shedding and subsequent scarless repair of
the functional upper layer of the endometrium. Perturbation of local glucocorticoid metabolism,
aberrant prostaglandin synthesis and excessive plasminogen (resulting in premature clot lysis) have all
been implicated in AUB [43].
AUB-Emay be implicated inmany womenwith AUB, but a lack of clinically available speciﬁc tests or
biomarkers means that practical testing for such disorders is not yet feasible. As such, diagnosis de-
pends on careful history taking and exclusion of other contributors. The high prevalence of potential
endometrial dysfunctionmeans that it is highly likely that thosewith AUB-L will often have an element
of AUB-E contributing to increased/aberrant menstrual blood loss with its attendant implication for
therapy.
Iatrogenic (AUB-I)
Iatrogenic causes of AUB include exogenous therapy than may lead to unscheduled endometrial
bleeding. This is typically associated with continuous oestrogen or progestin therapy (systemic or
intrauterine delivery routes) or those interventions that act on ovarian steroid release such as
gonadotropin-releasing hormone (GnRH) agonists and aromatase inhibitors. Selective oestrogen re-
ceptor modulators (SERMs) and more rarely selective progesterone receptor modulators (SPRMs) may
cause AUB through direct action on the endometrium.
The use of an intrauterine device (IUD) may cause a low-grade endometritis which may also
contribute to AUB.
Not otherwise classiﬁed (AUB-N)
It is inevitable that there will be pathologies that are either rare or poorly deﬁned that do not easily
ﬁt within the categories described earlier. Examples include arteriovenousmalformations, endometrial
pseudoaneurysms, myometrial hypertrophy and chronic endometritis (not precipitated by an IUD). All
of these can co-exist with AUB-L.
The planned regular review of the FIGO PALM-COEIN classiﬁcation system every 3e5 years through
FIGO [13] will allow reassessment, in particular, of this category. Further areas considered for future
sub-classiﬁcation include AUB-P and AUB-A.
Assessment of the patient presenting with AUB and ﬁbroids
As described earlier, all of the other causes of AUB may co-exist with ﬁbroids. As such, it is crucial
when a patient with known or suspected ﬁbroids presents with AUB, she is appropriately assessed for
the presence of other aetiologies. Misdiagnosis will have an impact on treatment options and efﬁcacy,
and in the event of undiagnosed coagulopathy, render surgical intervention disproportionately
hazardous.
As part of structured history, factors such as co-morbidities, polypharmacy, body mass index (BMI),
previous surgery and most crucially fertility desire and impact of pressure symptoms must be assessed
as these signiﬁcantly affect treatment approach. A structured approach is shown in Fig. 3.
An accurate menstrual history and associated symptoms will identify a likely AUB-O cause. As
described earlier, a structured screen for coagulopathies will identify 90% of those women with dis-
orders of systemic haemostasis (Table 2). History will also identify contributors to AUB-I.
Combined history and examinationwill suggest possible AUB-P/-A/-L and should be conﬁrmedwith
subsequent imaging. TV-USS remains the most acceptable and validated ﬁrst-line investigation. The
increasing use of saline infusion ultrasonography (SIS) and selected hysteroscopy will improve
sensitivity and speciﬁcity for diagnosis of polyps and SM ﬁbroids [37,44]. The optimal mode of imaging
for suspected adenomyosis has yet to be established [45]. Furthermore, womenwith ﬁbroids may have
them confused for focal adenomyosis and vice-versa using conventional imaging [27]. The increased
use of one-stop clinics with access to outpatient hysteroscopy improves patient satisfaction and fa-
cilitates timely investigation and management [46].
History
Menstrual
• Menarche
• Last menstrual period
• Menses frequency, regularity, duration and volume
• Intermenstrual bleeding and postcoital bleeding
Symptoms of anaemia
Sexual and Reproductive History
• Past pregnancies and mode of delivery
• Future fertility desire
• Subfertility
• Current contraceptive requirement
• Previous STIs
• Smear history
Associated Symptoms
• Pain
• Discharge
• Bowel and bladder symptoms in particular pressure
Systemic
• Weight change
• Coagulopathy history screen (Table 2)
• PCOS, liver, renal, thyroid, pituitary and adrenal disease
• Drug history: anti-platelet, anti-coagulant, tamoxifen,
hormones, HRT, dopamine agonists
Family history: VTE, malignancy
Social: impact of symptoms, smoking and occupation 
Examination
Basic observations: BP, BMI
Pallor
Signs of systemic disease
• Thyroid disease
• Bruising, petechiae
• Cushing’s
• Hyperandrogenism
Palpable pelvic mass
Speculum and bimanual
If indicated: smear, chlamydia screen, endometrial biopsy
Consider PR if appropriate
Investigation
Haemoglobin and consider ferritin
• If indicated: TFTs, gonadotrophins, PRL, HCG,
coagulopathy investigations
USS
MRI if required
Hysteroscopy if required
Fig. 3. Structured approach for assessing the patient presenting with AUB.
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uterine artery embolisation (UAE). As previously discussed, it is relatively poor at providing reassur-
ance of the absence of sarcomatous change.Endometrial sampling
In the UK, NICE recommend endometrial sampling in women with persistent inter-menstrual
bleeding or aged 45 years with treatment failure [3]. This has been highlighted in the RCOG guide-
lines with an exception of reducing the age of sampling in the context of treatment failure to 40 [47].
With the marked increase in endometrial cancer, the authors would encourage all gynaecologists to
continue to excise their clinical judgement for those women aged <40 years with HMB who have risk
factors for premalignant change such as obesity and PCOS. Endometrial sampling may be more chal-
lenging if ﬁbroids distort the cavity, and access to concurrent outpatient hysteroscopy can facilitate
timely exclusion of endometrial pathology.
Approach to management
Management of AUB-L should address fertility desire, impact of pressure symptoms, co-morbidities,
and any other AUB contributors. Treatment should be individualised. No one-size-ﬁts-all approaches
are available with regard to initial and subsequent treatment options, and there is a relative paucity of
large robust clinical trials providing head-to-head data rather to placebo.
In those with other underlying AUB causes co-existing with ﬁbroids, targeted treatment of these
may ameliorate bleeding, and in the absence of pressure symptoms or sub-mucosal myoma-related
infertility, all the treatmentsmay be required. Speciﬁc treatments for other causes are shown in Table 3.
Otherwise, treatment should be tailored depending on the impact of related symptoms, fertility
requirements and cavity distortion (Fig. 4). It should be remembered that a conservative approach
Table 3
Speciﬁc treatment options for individual PALM-COEIN causes of AUB.
AUB Sub-classiﬁcation Speciﬁc treatment
Polyp Resection
Adenomyosis Surgery: hysterectomy; adenomyomectomy (not frequently performed)
Malignancy Surgery þ/ adjuvant treatment
High-dose progestogens (if surgery not possible)
Palliation (including radiotherapy)
Coagulopathy Tranexamic acid
DDVAP
Ovulation Lifestyle modiﬁcation
Cabergoline (if hyperprolactinaemia)
Levothyroxine (if hypothyroid)
Endometrial Speciﬁc therapies await further delineation of underlying mechanisms
Iatrogenic Refer to FSRH CEU guidance on problematic bleeding with hormonal contraception [56]
Not otherwise classiﬁed Antibiotics for endometritis
Embolisation of AV malformation
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particularly in the peri-menopausal phase with amenorrhea and regression of ﬁbroid size imminent.
In AUB, in the absence of pressure symptoms, medical treatment may be more appropriate,
particularly when fertility preservation is required. Tranexamic acid and NSAIDs (e.g. mefenamic acid)
remain the only fully non-contraceptive medical options [3]. Whilst the risk of expulsion of a
levonorgestrel-releasing intrauterine system (LNGeIUS) is without doubt higher in the context of ﬁ-
broids, there is still evidence for efﬁcacy [48] although cavity distortion may preclude the use of
LNGeIUS.
The current Cochrane review for the SPRMs is limited to mifepristone [49] and a future review
incorporating other members of the SPRM class is underway. GnRH analogues are effective in reducing
both size of ﬁbroids and amelioration of bleeding, but their side effects and impact on bone densitySymptoms
AUB only AUB with pressure symptoms; family 
complete and no desire to retain 
fertility
AUB symptoms and fertility 
desire/subfertility
No cavity distortion LNG-IUS
Tranexamic acid
Mefenamic acid
UPA
GnRH analogue
P
UPA
GnRH analogue
Tranexamic acid
Mefenamic acid
UPA (short course)
GnRH analogue (short course)
UAE
EA
Hysterectomy
UAE
(MRgFUS)
Myomectomy
Hysterectomy
Myomectomy
UAE (evidence here needed)
(MRgFUS)
Cavity distortion Tranexamic acid
Mefenamic acid
UPA
GnRH analogue
P
UPA
GnRH analogue 
Tranexamic acid
Mefenamic acid
UPA (short course)
GnRH analogue (short course)
TCRF
UAE
Hysterectomy
UAE
Myomectomy
Hysterectomy
TCRF
Myomectomy 
UAE (evidence here needed)
Medical treatment
Surgical treatment
LNG-IUS Levonorgestrel-releasing -intrauterine system
UPA Ulipristal acetate
GnRH analogue Gonadotrophin-releasing hormone analogue
P Systemic progestogens
• Medroxyprogesterone acetate
• Norethisterone
• Depo-Medroxyprogesterone acetate
EA Endometrial ablation
UAE Uterine artery embolisation
(MRgFUS) MR-guided focused ultrasound – predominantly experimental at present
TCRF Transcervical resection of fibroid
Fig. 4. Symptom-based approach for management of AUB in the context of ﬁbroids.
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often are beneﬁcial as a short-term treatment prior to IVF or surgery, but given the ﬁndings in the
PEARL II study, there is good evidence that the SPRM ulipristal acetate (UPA) is better tolerated in those
women pre-surgery without loss of efﬁcacy [51]. There is no robust evidence for alternative therapies
such as acupuncture or herbal remedies for the treatment of ﬁbroids [52,53].
With regard to interventional radiological (uterine artery embolisation, UAE) and surgical options,
the anticipated outputs of the FEMME study [54] will hopefully provide robust evidence for impact on
symptoms and other qualitative measures between myomectomy and UAE. MR-guided focussed ul-
trasound (MRgFUS) is not a widely available technique. Its role in the management of symptomatic
ﬁbroids remains to be established. Hysterectomy is a deﬁnitive treatment, and in the context of
management options for HMB, it remains as a therapeutic option with the highest patient satisfaction
and cost-effectiveness for >5 years [55]. Hysterectomy, however, is often a challenging surgery in
women with high potential blood losses and risk of ureteric injury due to anatomical distortion in the
pelvis. With increasing obesity, the complexity of surgery is compounded.Whilst alternative treatment
strategies are under development, a cohort of womenwhose fertility plans are complete and for whom
deﬁnitive surgery, that is, hysterectomy, becomes the most appropriate management will remain.
Conclusions
AUB is a common and debilitating condition with high direct and indirect costs. Symptoms of AUB
frequently co-exist with ﬁbroids, but the relationship between AUB and ﬁbroids remains incompletely
understood. In many women, ﬁbroids may be an incidental innocent bystander in the underlying
aetiology of a menstrual bleeding complaint. A structured approach to establishing the cause using the
FIGO PALM-COEIN classiﬁcation systemwill facilitate accurate diagnosis and inform treatment options.
The classiﬁcation system, however, still lacks effective biomarkers for ‘AUB-E’. Ofﬁce hysteroscopy and
the increasingly sophisticated imagingwill assist provision of robust evidence for the underlying cause.
The increased availability of medical options has expanded the choice for women. Many will no longer
need to recourse to potentially complicated surgery. Treatment must remain individualised and
encompass the impact of pressure symptoms, desire for retention of fertility and contraceptive needs,
as well as address the management of their AUB in order to achieve improved quality of life.Practice points
 A structured approach for using the PALM-COEIN framework should be developed to ensure
that important contributors apart from fibroids are not missed.
 In particular, coagulopathies should be verbally screened for in all patients presenting with
AUB, given their high prevalence in this population and implications for management.
 In view of the rapid increase in endometrial cancer, clinical judgment regarding endometrial
sampling should be considered in younger women with AUB with risk factors for EIN and
malignancy.
 Treatment should be individualised encompassing impact of pressure symptoms, desire for
retention of fertility, contraceptive needs and impact of symptoms on quality of life.
Research agenda
 Imaging for fibroids, in particular, modality for diagnosis of adenomyosis and for discrimi-
nating between fibroids and leiomyosarcoma.
 Increased evidence base for long-term medical treatments for management of AUB in the
context of fibroids, with particular emphasis on quality of life.
 Improved evidence for interventional treatments for AUB in the context of fibroids.
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